



an Open Access Journal by MDPI

Mesenchymal-Stem-Cell-Based Drug Delivery Strategies for Biomedical Applications

Guest Editors:

Dr. Karolina Bajdak-Rusinek

Department of Medical Genetics,
Faculty of Medical Sciences in
Katowice, Medical University of
Silesia, Katowice, Medykow 18
Street, 40-752 Katowice, Poland

Dr. Agnieszka Fus-Kujawa

Department of Medical Genetics,
Faculty of Medical Sciences in
Katowice, Medical University of
Silesia, Katowice, Medykow 18
Street, 40-752 Katowice, Poland

Prof. Dr. Paweł Buszman

Department of Epidemiology,
Medical University of Silesia, 40-
055 Katowice, Poland

Deadline for manuscript
submissions:

closed (25 March 2024)

Message from the Guest Editors

Among various drug-targeting approaches, cell-based delivery systems offer some unique strengths. The use of mesenchymal stem cells as a targeted-delivery carrier is promising due to their ease of isolation, expansion, maintenance of their phenotype, and multilineage potential in vitro. Currently, MSC-based delivery represents a promising approach for several clinical applications, ranging from tissue repair to the treatment of pathologies such as diabetes, cardiovascular disease, neurological disorders, and cancer.

However, this approach still has many limitations in clinical translation, such as induction of immunogenicity, high costs, or variable effects. Moreover, the long-term effect of priming MSCs has not been evaluated yet. Further studies are needed to assess the impact of different priming approaches in clinic; the best sources for MSCs isolation; and the epigenetic modifications, immunogenicity, and tumorigenicity of primed and non-primed MSCs.

This Special Issue aims to present a collection of high-quality original articles and extensive reviews on MSC-based drug delivery systems for various clinical applications.



mdpi.com/si/168327

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)